RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PéROL M
Collezione AOU San Luigi di Orbassano

Items : 6

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. in The New England journal of medicine / N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21.

2023
AOU San Luigi di Orbassano

Zhou C; Solomon B; Loong HH; Park K; Pérol M; Arriola E; Novello S; Han B; Zhou J; Ardizzoni A; Mak MP; Santini FC; Elamin YY; Drilon A; Wolf J; Payakachat N; Uh MK; Rajakumar D; Han H; Puri T; Soldatenkova V; Lin AB; Lin BK; Goto K;

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Nov 1;41(31):4852-4863. doi: 10.1200/JCO.23.01361. Epub 2023 Sep 11.

2023
AOU San Luigi di Orbassano

Goto K; Goto Y; Kubo T; Ninomiya K; Kim SW; Planchard D; Ahn MJ; Smit EF; de Langen AJ; Pérol M; Pons-Tostivint E; Novello S; Hayashi H; Shimizu J; Kim DW; Kuo CH; Yang JC; Pereira K; Cheng FC; Taguchi A; Cheng Y; Feng W; Tsuchihashi Z; Jänne PA;

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10.

2022
AOU San Luigi di Orbassano

Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES;

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):763-773. doi: 10.2217/fon-2020-0935. Epub 2020 Nov 5.

2021
AOU San Luigi di Orbassano

Novello S; F Loong HH; Lin BK; Lin AB; Sashegyi A; Soldatenkova V; Davis HM; Elamin Y; Wolf J; Park K; Drilon A; Zhou CC; Solomon BJ; Arriola E; Pérol M; Goto K; Santini FC;

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2021 Jul;157:9-16. doi: 10.1016/j.lungcan.2021.05.017. Epub 2021 May 24.

2021
AOU San Luigi di Orbassano

Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S;

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. in ESMO open / ESMO Open. 2020 Jan;5(1):e000567. doi: 10.1136/esmoopen-2019-000567.

2020
AOU San Luigi di Orbassano

Garon EB; Scagliotti GV; Gautschi O; Reck M; Thomas M; Iglesias Docampo L; Kalofonos H; Kim JH; Gans S; Brustugun OT; Orlov SV; Cuyun Carter G; Zimmermann AH; Oton AB; Alexandris E; Lee P; Wolff K; Stefaniak VJ; Socinski MA; Pérol M;